Inflammatory syndrome in patients on hemodialysis

Journal of the American Society of Nephrology

Volumn 17, Issue SUPPL. 3, 2006, Pages

  Jofré, Rosa ^a   Rodriguez Benitez, Patrocinio ^a   López Gómez, Juan M ^a   Pérez Garcia, Rafael ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BIOCOMPATIBILITY; BLOOD LEVEL; CHRONIC DISEASE; COMORBIDITY; CONFERENCE PAPER; DIALYSATE; DISEASE MARKER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEREDITY; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATORY DISEASE; MORTALITY; OBESITY; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 33845254609     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006080926     Document Type: Conference Paper

References (82)

1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis. Kidney Int 55: 648-658, 1999
2. Barany P, Divino JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29: 565-568, 1997
3. Haverkate F, Thompson SG, Pype SDM, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349: 462-466, 1997
4. Bergstrom J, Heimburger O, Lindholm B, Qureshi AR: C-reactive protein as predictor for serum albumin and mortality in hemodialysis. J Am Soc Nephrol 6: 573-577, 1995
5. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476, 2000
6. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in dialytic patients. Nephrol Dial Transplant 19: 1154-1160, 2004
7. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17: 1684-1688, 2002
8. Conti G, Amore A, Chiesa M, Mancuso D, Cirina P, Mengozzi G, Santoro A, Coppo R: Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol 18: 282-288, 2005
9. Vaziri ND: Oxidative stress in uremia: Nature, mechanisms, and potential consequences. Semin Nephrol 24: 469-473, 2004
10. Jaar BG, Hermann JA, Furth SL, Briggs W, Powe NR: Septicemia in diabetic hemodialysis patients: Comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients. Am J Kidney Dis 35: 282-292, 2000
11. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38: 1408-1413, 2001
12. Kalousova M, Sulkova S, Fialova L, Soukupova J, Malbohan IM, Spacek P, Braun M, Mikulikova L, Fortova M, Horejsi M, Tesar V, Zima T: Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 18: 2577-2581, 2003
13. Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J, Himmelfarb J: Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 42: 286-294, 2003
14. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40: 1005-1012, 2002
15. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 22: 2212-2217, 2002
16. Ishimura E, Taniwaki H, Tabata T, Tsujimoto Y, Jono S, Emoto M, Shoji T, Inaba M, Inoue T, Nishizawa Y: Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis 45: 859-865, 2005
17. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
18. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 8: 827-833, 2003
19. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimburger O, Holmes C, Schalling M, Nordfors L: Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 67: 2383-2392, 2005
20. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47: 139-148, 2006
21. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67: 2295-2304, 2005
22. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ et al.: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 311: 711-714, 1995
23. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, Manttari M, Frick MH, Huttunen JK: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 116: 273-278, 1992
24. Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, Sweetnam PM, Elwood PC: Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 318: 1035-1040, 1999
25. Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F, Timio M: Inflammation, infection and cardiovascular events in chronic hemodialysis patients: A prospective study. J Nephrol 16: 245-251, 2003
26. Zoccali C, Mallamaci F, Tripepi G: Atherosclerosis in dialysis patients: Does Chlamydia pneumoniae infection contribute to cardiovascular damage? Nephrol Dial Transplant 17[Suppl 8]: 25-28, 2002
27. Kato A, Takita T, Maruyama Y, Hishida A: Chlamydial infection and progression of carotid atherosclerosis in patients on regular haemodialysis. Nephrol Dial Transplant 19: 2539-2546, 2004
28. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, Paroni R, Malatino LS: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 18: 1207-1213, 2000
29. Tsirpanlis G, Chatzipanagiotou S, Ioannidis A, Moutafis S, Poulopoulou C, Nicolaou C: Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells: Correlation with inflammation and atherosclerosis in haemodialysis patients. Nephrol Dial Transplant 18: 918-923, 2003
30. Lentine KL, Parsonnet J, Taylor I, Wrone EM, Lafayette RA: Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients. Clin Exp Nephrol 10: 55-62, 2006
31. Chen LP, Chiang CK, Chan CP, Hung KY, Huang CS: Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? Am J Kidney Dis 47: 815-822, 2006
32. Rahmati MA, Craig RG, Homel P, Kaysen GA, Levin NW: Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 40: 983-989, 2002
33. Kadiroglu AK, Kadiroglu ET, Sit D, Dag A, Yilmaz ME. Periodontitis is an important and occult source of inflammation in hemodialysis patients. Blood Purif 24: 400-404, 2006
34. Hussein MM, Mooij JM, Roujouleh H: Tuberculosis and chronic renal disease. Semin Dial 16: 38-44, 2003
35. Allon M, Daugirdas J, Depner TA, Greene T, Ornt D, Schwab SJ: Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis 47: 469-477, 2006
36. Movilli E, Brunori G, Camerini C, Vizzardi V, Gaggia P, Cassamali S, Scolari F, Cancarini GC: The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. Blood Purif 24: 387-393, 2006
37. Nassar GM, Fishbane S, Ayus JC: Occult infection of old nonfunctioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int 80: 49-54, 2002
38. Cai W, Zhu L, Chen X, Uribarri J, Peppa M: Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients. Am J Nephrol 26: 181-185, 2006
39. Chang CJ, Ko YS, Ko PJ, Hsu LA, Chen CF, Yang CW, Hsu TS, Pang JH: Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int 68: 1312-1319, 2005
40. Stenvinkel P, Pecoits-Filho R, Lindholm B; for the DialGene Consortium: Gene polymorphism association studies in dialysis: The nutrition-inflammation axis. Semin Dial 18: 322-330, 2005
41. Lopez-Gomez JM, Perez-Flores I, Jofre R, Carretero D, Rodriguez-Benitez P, Villaverde M, Perez-Garcia R, Nassar GM, Niembro E, Ayus JC: Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 15: 2494-2501, 2004
42. Garosi G, Di Paolo N: Inflammation and gross vascular alterations are characteristic histological features of sclerosing peritonitis. Perit Dial Int 21: 417-418, 2001
43. Eltoum MA, Wright S, Atchley J, Mason JC: Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Pent Dial Int 26: 203-206, 2006
44. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ: Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: Implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 18: 670-676, 2003
45. Macdougall IC, Cooper AC: Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 35[Suppl 3]: 32-35, 2005
46. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S: Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 29: 327-335, 2002
47. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hepcidin transcription by interleukin-1 and interleukin 6. Proc Natl Acad Sci USA 102: 1906-1910, 2005
48. Andrews NC: Anemia of inflammation: The cytokine-hepcidin link. J Clin Invest 113: 1251-1253, 2004
49. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC: Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood 100: 3776-3781, 2002
50. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY, Choi EJ, Chang YS, Bang BK: Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 40: 1230-1239, 2002
51. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, Li PK, Sanderson J: Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 14: 1871-1879, 2003
52. Losito A, Kalidas K, Santoni S, Jeffery S: Association of interleukin-6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 64: 616-622, 2003
53. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16: 335-340, 2001
54. Kim BS, Jeon DS, Shin MJ, Kim YO, Song HC, Lee SH, Kim SY, Choi EJ, Chang YS, Bang BK: Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol 25: 189-195, 2005
55. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK: Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 58: 900-906, 2000
56. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA: Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13: 1061-1066, 2002
57. Kopple JD: Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 83: 202-210, 2006
58. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW: Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 16: 2386-2394, 2001
59. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 62: 1791-1798, 2002
60. Kaizu Y, Tsunega Y, Yoneyama T, Sakao T, Hibi I, Miyaji K, Kumagai H: Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients. Clin Nephrol 50: 44-50, 1998
61. Zoccali C, Mallamaci F, Tripepi G: Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 19[Suppl 5]: S67-S72, 2004
62. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L: Adiponectin in renal disease: Relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274-281, 2004
63. Ramirez R, Carracedo J, Berdud I, Carretero D, Merino A, Rodriguez M, Tetta C, Martin-Malo A, Aljama P: Microinflammation in hemodialysis is related to a preactivated subset of monocytes. Hemodial Int 10[Suppl 1]: S24-S27, 2006
64. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int Suppl 78: S271-S277, 2001
65. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-176, 2002
66. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson E: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15: 2186-2194, 2004
67. Al-Hejaili F, Kortas C, Leitch R, Heidenheim AP, Clement L, Nesrallah G, Lindsay RM: Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 14: 2322-2328, 2003
68. De los Reyes B, Navarro JA, Perez-Garcia R, Liras A, Campos Y, Bornstein B, Arenas J: Effects of L-carnitine on erythrocyte acyl-CoA, free CoA and glycerophospholipid acyltransferase in uremia. Am J Clin Nutr 67: 386-390, 1998
69. Galli F, Benedetti S, Floridi A, Canestrari F, Piroddi M, Buoncristiani E, Buoncristiani U: Glycosylation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 67: 750-759, 2005
70. Lago M, Perez Garcia R, Arenas J, De los Reyes B, Anaya F, Garcia de Vinuesa MS, Dall'Anese C, Valderrabano F: Carnitine losses in hemodialysis: Influence of different dialyzers and its relationship with nutritional status. Nefrologia 15: 55-61, 1995
71. De Leo FR, Renee J, McCormick S, Nakamura M, Apicella M, Weiss JP: Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Invest 101: 455-463, 1998
72. Morena M, Cristol JP, Canaud B: Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif 18: 191-199, 2000
73. Amore A, Coppo R: Acetate intolerance and synthesis of nitric oxide by endothelial cells. J Am Soc Nephrol 8: 1431-1436, 1997
74. Coll E, Perez-Garcia R, Rodriguez-Benitez P, Ortega M, Martinez P, Jofre R, Lopez-Gomez JM: Hemodialysis without acetic acid: Clinical and analytical changes [Abstract]. J Am Soc Nephrol 16: 442A, 2005
75. Amore A, Cirina P, Bonaudo R, Conti G, Chiesa M, Coppo R: Bicarbonate dialysis, unlike acetate-free biofiltration, triggers mediators of inflammation and apoptosis in endothelial and smooth muscle cells. J Nephrol 19: 57-64, 2006
76. Panichi V, Migliori M, De Pietro S, Metelli MR, Taccola D, Perez Garcia R, Palla R, Rindi P, Cristofani R, Tetta C: Plasma C-reactive protein in hemodialysis patients: A cross-sectional, longitudinal clinical survey. Blood Purif 18: 30-36, 2000
77. Perez-Garcia R, Anaya F, Chisvert J, Valderrabano F: Association of high-flux dialysers and bacterial contamination of dialysate induced chronic release of cytokines in haemodialysis patients. Nephrol Dial Transplant 11: 2164-2166, 1995
78. G. Lonnemann: Dialysate bacteriological quality and the permeability of dialyzer membranes to pyrogens. Kidney Int 43[Suppl 41]: 195-200, 1993
79. Pertosa G, Gesualdo L, Bottalico D, Schena FP: Endotoxins modulate chronically tumour necrosis factor alpha and interleukin 6 release by uraemic monocytes. Nephrol Dial Transplant 10: 328-333, 1995
80. Sundaram S, King AJ, Pereira BJ: Lipopolysaccharide-binding protein and bactericidal/permeability-increasing factor during hemodialysis: Clinical determinants and role of different membranes. J Am Soc Nephrol 8: 463-470, 1997
81. Gimdt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Buschenfelde KHM, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 47: 559-565, 1995
82. Scherberich JE, Nockher WA: Blood monocyte phenotypes and soluble endotoxin receptor CD14 in systemic inflammatory diseases and patients with chronic renal failure. Nephrol Dial Transplant 15: 574-577, 2000